Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Site Search
This month, 15-year-old Molly Bonnell and her sister Emily, 13, who have cystic fibrosis, discovered how easy it is to make their voices heard in Congress -- without leaving their living room.
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
The 24th annual Ultimate Golf Experience brought together a standout array of entertainers, guests, and friends of the Cystic Fibrosis Foundation for a premier golfing event to raise funds in the fight against cystic fibrosis.
Meb Keflezighi, one of the world's best runners, joined Lee University and ran in the 65 Roses 5K in Cleveland, Tenn. to support the fight against cystic fibrosis. Lee University was thrilled to welcome him as part of its longstanding tradition of raising funds in support of the CF Foundation's mission.
Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.